Last updated: August 18, 2026
Hydroxyzine hydrochloride is a mature, low-cost generic with no meaningful remaining originator exclusivity, no biosimilar exposure, and limited patent-driven pricing power. Demand is supported by anxiety, pruritus, urticaria, and perioperative or procedural use, while revenue is constrained by generic substitution, multiple suppliers, low unit prices, and competition from hydroxyzine pamoate, cetirizine, diphenhydramine, non-sedating antihistamines, and newer anxiolytic therapies. Public sources do not report a reliable standalone global revenue figure for hydroxyzine hydrochloride.
Hydroxyzine Hydrochloride Market Dynamics, Patent Status, and Financial Trajectory
What is hydroxyzine hydrochloride and how is it used?
Hydroxyzine hydrochloride is a first-generation antihistamine and central nervous system depressant. U.S. labeling identifies it for symptomatic relief of anxiety and tension, management of pruritus caused by allergic conditions, and use as a preoperative sedative. It is available primarily as tablets, capsules, and oral solution or syrup, depending on market and manufacturer [1].
Hydroxyzine hydrochloride is the hydrochloride salt of hydroxyzine. Hydroxyzine pamoate is a separate salt form sold historically under the Vistaril brand and through generic products. The two salts contain the same active moiety but have different product formulations and labeling histories.
| Attribute |
Hydroxyzine hydrochloride |
| Drug class |
First-generation antihistamine |
| Pharmacologic activity |
H1 receptor antagonist with sedative and anxiolytic effects |
| Main labeled uses |
Anxiety, pruritus, preoperative sedation |
| Common dosage forms |
Tablets, capsules, oral solution, syrup |
| U.S. regulatory status |
Prescription generic drug |
| Originator brand |
Atarax historically associated with hydrochloride products |
| Current patent leverage |
No meaningful active composition-of-matter exclusivity |
| Biosimilar risk |
None |
| Primary commercial constraint |
Generic price competition |
Hydroxyzine is also prescribed off label for insomnia, acute agitation, nausea, and short-term symptomatic anxiety. Off-label use supports prescription volume but does not create additional exclusivity or materially improve manufacturers’ pricing power.
When does hydroxyzine hydrochloride lose exclusivity?
Hydroxyzine hydrochloride lost practical market exclusivity decades ago. The active pharmaceutical ingredient and early branded products date to the mid-20th century. Any original composition-of-matter or pioneering product patents would have expired long before the modern generic drug market.
The commercial position is therefore defined by abbreviated new drug applications, manufacturing capability, regulatory compliance, and wholesaler access rather than patent protection.
| Exclusivity category |
Current position |
| New chemical entity exclusivity |
Expired |
| Composition-of-matter patent |
Expired |
| Original product patent |
Expired |
| FDA orphan exclusivity |
None identified |
| Pediatric exclusivity |
None relevant to current market position |
| New formulation exclusivity |
No material current exclusivity identified |
| Generic competition |
Established |
| Reference listed drug protection |
No meaningful commercial barrier |
The FDA Orange Book identifies patents and regulatory exclusivity for approved products when applicable. Hydroxyzine hydrochloride is not generally associated with an active Orange Book patent estate that would delay ordinary generic competition [2].
What patents protect hydroxyzine hydrochloride?
No active patent estate is generally known to protect the hydroxyzine hydrochloride molecule, its original therapeutic use, or conventional oral dosage forms in the United States.
Composition-of-matter patents
Hydroxyzine was developed and commercialized many decades ago. Any early patents covering the molecule or its basic salts have expired. A new patent directed only to the old active ingredient would generally face novelty and obviousness barriers under modern patent standards.
Formulation patents
Conventional tablets, capsules, syrups, and oral solutions have no apparent commercially significant patent barrier. A company could pursue a patent for a genuinely novel delivery system, modified-release profile, combination product, or manufacturing process, but such a patent would protect only the qualifying technology. It would not prevent generic manufacturers from selling ordinary immediate-release hydroxyzine hydrochloride.
Method-of-use patents
The core uses of hydroxyzine, including pruritus, anxiety, and preoperative sedation, are long established. No major active method-of-use patent is known to control the mainstream U.S. market.
Manufacturing and process protection
Manufacturing know-how may remain confidential, particularly around crystallization, impurity control, yield optimization, and liquid formulation stability. Trade secrets can affect production economics but do not provide the exclusionary position of a patent. Multiple manufacturers and contract manufacturers can generally produce the active ingredient or finished dosage forms under applicable quality standards.
What is the Orange Book status of hydroxyzine hydrochloride?
Hydroxyzine hydrochloride has no meaningful current Orange Book listing that creates a commercial barrier to generic entry. FDA approval is based on the reference product and the ANDA pathway for therapeutically equivalent products where applicable [2].
The practical implications are:
- No active patent listing is expected to block an ANDA applicant.
- Paragraph IV litigation is not a central market issue.
- Generic applicants do not need to negotiate a patent settlement to enter the ordinary market.
- Product-specific exclusivity is not the principal commercial variable.
- Approval and launch depend primarily on FDA review, manufacturing readiness, supply economics, and commercial contracting.
The status of an individual product can differ by dosage form, strength, or manufacturer. Discontinued reference products and legacy listings may also remain visible in historical FDA records without creating current market protection.
Which companies are challenging hydroxyzine hydrochloride patents?
No major current Paragraph IV campaign is associated with hydroxyzine hydrochloride. The market already contains generic competition, so there is no material originator patent position for challengers to attack.
Potential suppliers include generic pharmaceutical companies, contract manufacturers, and regional distributors. The relevant competitive process is supplier entry and product availability rather than patent litigation.
What patent litigation affects hydroxyzine hydrochloride?
No major ongoing U.S. patent litigation is broadly associated with the conventional hydroxyzine hydrochloride market. Any disputes are more likely to involve:
- Product quality or manufacturing compliance.
- Supply contracts.
- Trademark or labeling issues.
- Formulation-specific products.
- Regulatory enforcement.
- Private commercial disputes between manufacturers and distributors.
These issues can affect individual suppliers without changing the market-wide freedom to operate for standard hydroxyzine hydrochloride products.
Are there settlement agreements affecting generic entry?
No commercially significant patent settlement controlling generic entry is generally associated with hydroxyzine hydrochloride. Generic entry occurred after the relevant originator rights had expired, reducing the need for delayed-entry settlements.
What is the FDA regulatory status of hydroxyzine hydrochloride?
Hydroxyzine hydrochloride is an FDA-approved prescription drug available through generic products. The FDA-approved labeling describes its antihistaminic, anxiolytic, and sedative uses [1].
The drug is subject to the standard regulatory requirements applicable to prescription generics, including:
- ANDA approval or other applicable FDA approval pathway.
- Current good manufacturing practice compliance.
- Stability and container-closure requirements.
- Accurate labeling and dosage instructions.
- Pharmacovigilance and adverse-event reporting.
- Controlled management of manufacturing changes.
Hydroxyzine is not federally scheduled under the Controlled Substances Act. Its sedative properties can still create clinical and commercial restrictions. Labeling and clinical practice recognize central nervous system depression and the risk of additive effects with alcohol and other sedatives [1].
Regulatory risk has also increased around QT prolongation and cardiac arrhythmia concerns. The European Medicines Agency restricted hydroxyzine use in patients with risk factors for QT interval prolongation and recommended dose and duration limits in higher-risk populations [3]. These restrictions can influence prescribing, hospital formularies, and market growth even though they do not create patent risk.
How large is the hydroxyzine hydrochloride market?
A reliable, public, drug-specific global revenue figure is not available from standard regulatory or company disclosures. Hydroxyzine hydrochloride is sold by multiple generic manufacturers, and public companies generally do not report product-level revenue for this molecule.
Market research reports often combine hydroxyzine hydrochloride and hydroxyzine pamoate, or group hydroxyzine with broader antihistamine, anxiolytic, or dermatology markets. Such estimates are not directly comparable unless they define:
- Salt form.
- Dosage form.
- Prescription versus retail channels.
- Geographic coverage.
- Branded and generic products.
- Revenue versus volume.
- Hospital and institutional purchases.
The most defensible commercial conclusion is that hydroxyzine hydrochloride is a high-volume, low-value generic opportunity rather than a large branded pharmaceutical franchise.
What drives demand?
Demand is supported by several clinical segments:
| Demand segment |
Commercial effect |
| Pruritus and urticaria |
Supports recurring outpatient use |
| Anxiety |
Supports prescriptions where short-term symptomatic treatment is appropriate |
| Preoperative sedation |
Creates institutional and procedural demand |
| Insomnia and agitation |
Adds off-label volume but faces safety and guideline limits |
| Pediatric liquid use |
Supports oral-solution and syrup demand where clinically appropriate |
| Emergency and inpatient use |
Supports hospital purchasing and stock requirements |
Use can decline when clinicians favor non-sedating antihistamines, behavioral interventions, selective serotonin reuptake inhibitors, buspirone, newer sleep therapies, or disease-specific antipruritic treatments.
What is the financial trajectory for hydroxyzine hydrochloride?
The financial trajectory is mature to declining in price, with relatively stable underlying demand and limited upside from innovation.
Revenue profile
Manufacturer revenue is shaped by unit volume multiplied by a low net price. A supplier can increase sales through:
- Winning additional wholesaler contracts.
- Maintaining uninterrupted supply during shortages.
- Adding strengths or dosage forms.
- Securing hospital and institutional contracts.
- Improving manufacturing yield.
- Selling in markets with less aggressive price competition.
Revenue expansion from price increases is difficult because buyers can switch among multiple generic suppliers. A price increase can cause rapid loss of formulary or distributor share.
Margin profile
Gross margins vary sharply by supplier. They are typically better for manufacturers with:
- Efficient active ingredient sourcing.
- High plant utilization.
- Reliable regulatory compliance.
- Broad distribution.
- Low-cost oral liquid production.
- Strong hospital contracting capabilities.
Margins can deteriorate when several suppliers compete for the same contracts or when raw-material costs rise. Oral liquids may offer more operational complexity than tablets because of stability, microbial control, packaging, and shipping requirements.
Financial trajectory by period
| Period |
Market and financial characteristics |
| 1950s-1980s |
Originator and early branded market |
| 1980s-2000s |
Broad generic entry and loss of pricing power |
| 2000s-2010s |
Mature prescription market with low unit economics |
| 2020s |
Stable clinical demand, generic competition, supply-chain sensitivity |
| Forward outlook |
Low nominal growth, periodic price volatility, limited innovation premium |
Hydroxyzine may produce attractive aggregate industry revenue because it is inexpensive and widely prescribed, but individual-product revenue is generally modest. No public evidence supports treating it as a high-growth pharmaceutical asset.
What generic entry risks exist for hydroxyzine hydrochloride?
Traditional generic entry risk is already realized. The market is exposed to a different set of risks:
Supply and manufacturing risk
A manufacturer may experience:
- Active ingredient shortages.
- Quality-control failures.
- FDA warning letters or import alerts.
- Facility shutdowns.
- Packaging shortages.
- Liquid formulation interruptions.
- Wholesaler delisting.
Because generic prices are low, manufacturers may exit if margins no longer cover compliance and production costs.
Substitution risk
Hydroxyzine can lose demand to:
- Cetirizine, loratadine, and other less-sedating antihistamines for allergy and urticaria.
- Topical or targeted therapies for pruritus.
- Buspirone or antidepressants for chronic anxiety.
- Newer insomnia medicines.
- Nonpharmacologic treatment.
- Hospital protocols that limit sedating antihistamines.
Safety-related risk
Sedation, anticholinergic effects, falls, cognitive impairment, and cardiac safety concerns may reduce use in older adults and medically complex patients. The American Geriatrics Society Beers Criteria identifies hydroxyzine as a potentially inappropriate medication for many older adults because of strong anticholinergic effects [4].
How does hydroxyzine hydrochloride compare with hydroxyzine pamoate?
Hydroxyzine hydrochloride and hydroxyzine pamoate are alternative salt forms of hydroxyzine. Both are genericized and lack meaningful modern patent exclusivity.
| Factor |
Hydroxyzine hydrochloride |
Hydroxyzine pamoate |
| Common historical brand association |
Atarax |
Vistaril |
| Typical dosage forms |
Tablets, capsules, oral solution, syrup |
Capsules and oral products depending on market |
| Main uses |
Anxiety, pruritus, sedation |
Anxiety, pruritus, sedation |
| Patent position |
Expired |
Expired |
| Generic competition |
Established |
Established |
| Commercial distinction |
Formulation, availability, contracting |
Formulation, availability, contracting |
| Biosimilar exposure |
None |
None |
Prescribers and pharmacies may substitute between salt forms only under applicable laws and product-specific rules. Salt-form interchangeability should not be assumed solely because the active moiety is the same.
What licensing deals affect hydroxyzine hydrochloride?
No major current licensing transaction is known to define the hydroxyzine hydrochloride market. The drug is generally commercialized through generic manufacturing, distribution, and contract supply arrangements rather than strategic licenses.
Relevant commercial agreements are likely to be private and may include:
- API supply contracts.
- Contract manufacturing arrangements.
- Private-label distribution.
- Hospital group purchasing agreements.
- Regional marketing rights.
- Technology-transfer agreements for oral liquids.
These agreements may change supplier share without affecting patent exclusivity.
What geographic markets are most relevant?
The United States is a mature generic market governed by FDA approval and pharmacy benefit substitution. Europe is also mature, but national reimbursement systems, reference pricing, and hydroxyzine safety restrictions can produce different demand patterns [3].
Key geographic variables include:
- Prescription reimbursement.
- National formulary placement.
- Local generic substitution rules.
- Availability of oral liquids.
- API sourcing from Asia and Europe.
- Hospital procurement concentration.
- Regulatory restrictions on sedating antihistamines.
- Local treatment preferences for anxiety and allergy.
Emerging markets may have higher over-the-counter or nonstandard use, but regulatory classification and reporting quality vary. Geographic expansion is more likely to deliver incremental volume than premium pricing.
How strong is the hydroxyzine hydrochloride patent estate?
The patent estate is weak from an exclusion perspective because the core molecule, established uses, and conventional formulations are old and genericized. Its commercial defensibility depends on execution rather than intellectual property.
| Strength factor |
Assessment |
| Core molecule protection |
None remaining |
| Basic therapeutic-use protection |
None material |
| Conventional formulation protection |
None material |
| Patent litigation leverage |
Minimal |
| Regulatory exclusivity |
None material |
| Manufacturing know-how |
Potentially useful but nonexclusive |
| Supply reliability |
Commercially important |
| Brand differentiation |
Limited |
| Switching barriers |
Low |
Key Takeaways
- Hydroxyzine hydrochloride is a mature generic prescription drug with no meaningful active patent exclusivity.
- The FDA Orange Book does not provide a material current patent barrier to standard generic competition.
- Paragraph IV challenges, patent settlements, and biosimilar risk are not central market issues.
- Demand comes from anxiety, pruritus, urticaria, sedation, and off-label uses such as insomnia.
- Revenue is difficult to quantify because manufacturers do not generally disclose product-level sales.
- The financial profile is low price, established volume, thin-to-moderate supplier margins, and high sensitivity to contracts and manufacturing efficiency.
- Safety concerns, especially sedation, anticholinergic burden, and QT prolongation, limit long-term growth.
- The main commercial risks are supply interruption, regulatory compliance, price erosion, and substitution by newer or less-sedating therapies.
- Hydroxyzine hydrochloride and hydroxyzine pamoate compete as alternative salt forms but have similar generic and patent profiles.
- Manufacturing reliability and distribution access matter more than patent ownership.
FAQs
Is hydroxyzine hydrochloride still under patent?
No material active patent protection is generally associated with the conventional hydroxyzine hydrochloride molecule or standard oral products. The relevant original rights expired decades ago.
Can a generic manufacturer launch hydroxyzine hydrochloride without a Paragraph IV filing?
Yes. Because no material current patent barrier generally controls standard hydroxyzine hydrochloride products, a manufacturer can pursue the applicable FDA generic approval route without relying on a patent challenge to obtain market entry.
Is hydroxyzine hydrochloride a controlled substance?
No. Hydroxyzine is not federally scheduled as a controlled substance in the United States. It remains a prescription drug with clinically relevant sedative and anticholinergic effects.
Does hydroxyzine hydrochloride have biosimilar competition?
No. Biosimilars apply to biological products. Hydroxyzine hydrochloride is a small-molecule chemical drug and competes through generic products.
Is hydroxyzine hydrochloride commercially attractive for pharmaceutical companies?
It can be commercially viable for efficient generic manufacturers with reliable supply, low production costs, and strong distribution. It is generally unattractive as a premium-priced or patent-protected asset because the market has low prices, limited differentiation, and substantial substitution risk.
References
-
U.S. National Library of Medicine. (n.d.). Hydroxyzine hydrochloride: DailyMed drug label. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
European Medicines Agency. (2015). Hydroxyzine-containing medicinal products: Referral. https://www.ema.europa.eu/
-
American Geriatrics Society Beers Criteria Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052-2081.
